Chapter 55: Female Reproductive Health Drug Therapy

Female Reproductive Health Drug Therapy educational resource explores the pharmacological management of female reproductive health, providing a detailed overview of treatments ranging from contraception to postmenopausal bone health. The chapter begins with a thorough examination of combined hormonal contraceptives, including oral tablets, transdermal patches, and vaginal rings, explaining how synthetic estrogen and various generations of progestins function to suppress the luteinizing hormone surge, prevent ovulation, and modify cervical mucus. It places heavy emphasis on nursing assessment and patient safety, particularly identifying contraindications like tobacco use, which significantly increases the risk of serious cardiovascular complications such as myocardial infarction and venous thromboembolism. For individuals unable to tolerate estrogen, the text reviews progestin-only methods like the minipill and injectable medroxyprogesterone acetate, noting the importance of monitoring bone mineral density during long-term use. The curriculum also covers the management of common menstrual disorders, including polycystic ovarian syndrome (PCOS), endometriosis, and abnormal uterine bleeding, highlighting the roles of nonsteroidal anti-inflammatory drugs (NSAIDs) and gonadotropin-releasing hormone (GnRH) agonists in alleviating chronic pelvic pain. Furthermore, the discussion on fertility addresses the induction of ovulation using selective estrogen receptor modulators and aromatase inhibitors, while cautioning against the risks of multiple gestation and ovarian hyperstimulation syndrome. As the reproductive cycle concludes, the chapter details the stages of menopause and the application of hormone therapy for vasomotor symptoms, stressing the importance of using the lowest effective dose over the shortest duration to minimize risks. The final section focuses on the prevention and treatment of osteoporosis through pharmacological agents such as bisphosphonates, selective estrogen receptor modulators (SERMs), and monoclonal antibodies, integrated with essential lifestyle interventions including weight-bearing exercise and optimized intake of calcium and vitamin D to maintain skeletal integrity.